Yearly Dosing Focus

In addition to wet AMD, Ocular streamlined its diabetic retinopathy (DR) program to focus on HELIOS‑3, a single registrational superiority study evaluating once‑yearly (Q12M) dosing of AXPAXLI. Market research indicates strong physician preference for a once‑yearly treatment paradigm, and a single global trial is expected to enhance commercial advantages.